Muaz Alsabbagh, MD1, Ahmed El Telbany, MD, MPH2, Khaled Alsabbagh Alchirazi, MD3, Thabet Qapaja, MD1, Mhd Kutaiba Albuni, MD4, Miguel D Regueiro, MD1 1Cleveland Clinic, Cleveland, OH; 2University of New Mexico, Albuquerque, NM; 3Aurora Healthcare, Brookfield, WI; 4TriHealth Good Samaritan Hospital, Cincinnati, OH
Introduction: Men with IBD have a higher risk of sexual and gonadism dysfunction. The Janus Kinase inhibitors (JAKi) may impact sperm production and contribute to hypogonadism. Our research aims to assess the impact of JAKi on male sexual health.
Methods: We conducted a 5-year retrospective analysis using the using TriNetX (2018-2023) of all patients who had IBD diagnoses. We identified patients with IBD who received JAKi. The IBD control cohort included patients with IBD who did not receive JAKi. 1:1 propensity-score matching (PSM) was performed for age, gender, race, ethnicity, known co-morbid conditions and IBD activity. Men's sexual-related outcomes, as defined as testicular hypofunction, decreased libido, erectile dysfunction, and male infertility, were assessed at 1,3- and 5-yearspost-treatment initiation. Adjusted hazards ratios (HR) with 95% confidence intervals (CI) were calculated to estimate the effect of JAKi therapy on these outcomes.
Results: After PSM, our study included 2,520 IBD patients in both cohorts. The comparison of men's sexual health outcomes between those on JAKi and those not on JAKi over 1, 3 and years showed no significant differences. Specifically, testicular hypofunction (HR = 1.05, 95% CI [0.42, 2.64]), decreased libido (HR [0.95, 0.41, 2.19]), erectile dysfunction (HR 1.55, [0.88, 2.72]), and male infertility (HR 3.30, [0.34, 31.76]) were not significantly affected by JAKi.
Discussion: Our findings suggest that JAKi therapy does not impact sexual health in male IBD patients. Based on the data thus far, JAKi do not need to be stopped in men trying to conceive a pregnancy.
Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
Disclosures:
Muaz Alsabbagh indicated no relevant financial relationships.
Ahmed El Telbany indicated no relevant financial relationships.
Khaled Alsabbagh Alchirazi indicated no relevant financial relationships.
Thabet Qapaja indicated no relevant financial relationships.
Mhd Kutaiba Albuni indicated no relevant financial relationships.
Miguel D Regueiro: AbbVie – Advisory Committee/Board Member, Consultant, Speakers Bureau.
Muaz Alsabbagh, MD1, Ahmed El Telbany, MD, MPH2, Khaled Alsabbagh Alchirazi, MD3, Thabet Qapaja, MD1, Mhd Kutaiba Albuni, MD4, Miguel D Regueiro, MD1. P4309 - Janus Kinase Inhibitors Do Not Impact Male Sexual Health or Fertility Outcomes in IBD Patients, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
